Udenafil (Standard)
Udenafil (Standard) is the analytical standard of Udenafil. This product is intended for research and analytical applications. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98%
- No. CAS: 268203-93-6
- Fòrmula: C25H36N6O4S
- Peso molecular:516.66
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-18253
UdenafilPDE Inhibitor -
HY-17464
CilostazolPDE3 Inhibitor -
HY-14252
Milrinone -
HY-90009A
TadalafilPDE5 Inhibitor -
HY-12085
ApremilastPDE-4 Inhibitor -
HY-16900
RolipramPDE4 Inhibitor -
HY-15455
RoflumilastPDE4 Inhibitor -
HY-15025
SildenafilPDE5 Inhibitor -
HY-B0204
PimobendanPDE Inhibitor -
HY-12318
IBMXPDE Inhibitor -
HY-12085R
Apremilast (Standard)PDE-4 Inhibitor -
HY-N0014
IcariinPPAR Activator
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 268203-93-6
-
Peso molecular 516.66
-
Fòrmula C25H36N6O4S
-
SMILES
O=S(C1=CC=C(OCCC)C(C2=NC3=C(N(C)N=C3CCC)C(N2)=O)=C1)(NCCC4N(C)CCC4)=O
-
Synonyms
DA8159 (Standard)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53. [Content Brief]
[2]. Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Udenafil (Standard) Related Classifications
HY-18253R Related Classifications
Powered by Bioz